{"doi":"10.1002/slct.202400680","title":"2‐(1‐Methyl‐1 <i>H</i> ‐indazol‐5‐yl)‐ <i>N</i> ‐arylisonicotinamide Analogs: Synthesis, Anticancer Screening, SAR and ADMET Studies","abstract":"Abstract In this current research framework, we detailed the synthesis of ten novel 2‐(1‐methyl‐1 H ‐indazol‐5‐yl)‐N‐arylisonicotinamide analogs ( 3a – j ). The synthesis of these compounds ( 3a – j ) involved a three‐step process, employing the Suzuki‐Miyaura coupling reaction, which successfully linked 1‐methyl‐1 H ‐indazole with isonicotinamide to satisfactory yields. The synthesized compounds were characterized using various spectroscopic techniques. To assess their potential, the anticancer activity of compounds ( 3a – j ) was evaluated following the National Cancer Institute (NCI US) protocol against nine panels comprising different cancer cell lines, at a concentration of 10 −5 M. Growth percentage (GP) and percentage growth inhibition (PGI) were calculated for each compound. Notably, the CNS cancer cell line SNB‐75 exhibited a remarkable PGI of 99.16 percent, indicating high sensitivity to the tested compound 3e . Additionally, ADMET prediction suggested that most of the synthesized compounds possess drug‐like properties, with low adverse effects and toxicity. These findings represent a significant advancement, offering potential avenues for further developments in the field of cancer research.","journal":"ChemistrySelect","year":2024,"id":496938,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9451,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1343679,"name":"Parth Unjiya","orcid":"0009-0002-6348-8421","position":1,"is_corresponding":false},{"id":1343680,"name":"Ranjitsinh C. Dabhi","orcid":"0000-0002-9519-2978","position":2,"is_corresponding":false},{"id":1343883,"name":"Hemal Parmar","orcid":null,"position":3,"is_corresponding":false},{"id":1343884,"name":"Manish Shah","orcid":null,"position":4,"is_corresponding":false},{"id":1343678,"name":"Umang P. Patel","orcid":"0009-0002-9479-8828","position":0,"is_corresponding":true}],"reference_count":27,"raw_metadata":null,"created_at":"2026-07-19T02:09:30.779495Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}